Akros Pharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Akros Pharma Inc. - overview
Established
1999
Location
Princeton, NJ, US
Primary Industry
Pharmaceuticals
About
Based in the US, Akros Pharma Inc. is a pharmaceutical company focused on developing innovative therapeutic candidates for various medical conditions. Its expertise lies in addressing complex health issues with advanced drug solutions. Akros Pharma Inc.
specializes in the development of therapeutic candidates for multiple medical conditions, including autoimmune diseases and chronic heart failure. Founded in 1999 in Princeton, US, the company has engaged in one significant deal. In May 2025, SHIONOGI agreed to fully acquire the company for USD 23 mn, aiming to enhance its antiviral pipeline and research capabilities. Akros has raised a total of USD 23.
776 mn and its latest funding round was LP Direct, involving investments from SHIONOGI. Akros Pharma Inc. specializes in innovative pharmaceutical products aimed at treating various medical conditions such as autoimmune diseases, type 2 diabetes mellitus, chronic heart failure, neurodegenerative diseases, and pulmonary arterial hypertension. Key products in development include JTE-051, an interleukin-2 inducible T cell kinase inhibitor, and JTT-662, an SGLT1 inhibitor, both targeting essential physiological mechanisms to improve patient outcomes.
The company operates in both US and global markets to meet diverse healthcare needs. Akros Pharma Inc. 's revenue model is centered around partnerships and collaborations within the pharmaceutical sector, primarily as the US arm of JT Pharmaceuticals. The company engages in licensing agreements for its drug candidates, focusing on therapeutics that advance through various clinical trial phases.
Its flagship products, currently in Phase 1 and Phase 2 clinical trials, underpin future revenue potential as they move towards market approval and commercialization. Following the acquisition by SHIONOGI in May 2025, Akros Pharma Inc. plans to leverage the additional resources to enhance its antiviral pipeline and accelerate the development of innovative treatments. The recent funding will support the ongoing development of its pipeline products and facilitate expansion into new therapeutic areas.
With the backing of SHIONOGI, the company aims to strengthen its market presence in both existing and new geographic regions.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.akrospharma.com
Verticals
HealthTech, Manufacturing
Total Amount Raised
Subscriber access only
Akros Pharma Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Announced | Akros Pharma Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.